Potential PET tracers for imaging of tumor-associated macrophages
Tóm tắt
The increasing incidence of cancer over the years is one of the most challenging problems in healthcare. As cancer progresses, the recruitment of several immune cells is triggered. Infiltration of tumor-associated macrophages (TAMs) is correlated with poor patient prognosis. Since TAMs constitute a big portion of the tumor mass, targeting these cells seems to be an attractive approach for cancer immunotherapy. Additionally, TAM assessment using non-invasive imaging techniques, such as positron emission tomography (PET), might provide a better understanding of the role of TAMs in cancer, and a means for tumor profile characterization, patient selection for individualized immunotherapy and treatment monitoring. Imaging of TAMs using PET tracers is still in its infancy. TAMs have several characteristics that could be exploited as potential targets for imaging. Various PET tracers for these TAM biomarkers have been developed, although often in the context of (neuro)inflammatory diseases rather than cancer. Since macrophages in inflammatory diseases express similar biomarkers as TAMs, these PET tracers could potentially also be applied for the assessment of TAMs in the tumor microenvironment. Therefore, the present review provides an overview of the TAM biomarkers, for which potential PET tracers are available and discusses the status of these tracers.
Tài liệu tham khảo
Biodistribution, tumor detection, and radiation dosimentry of [18F]-AZAFOL as positron emission tomography (PET) tracer in folate receptor positive cancer imaging. 2017 [cited 28 Jul 2021]. https://clinicaltrials.gov/ct2/show/NCT03242993.
Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392(6676):565–8.
Bigalke B, et al. PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). Int J Cardiol. 2014;177(1):287–91.
Blykers A, et al. PET imaging of macrophage mannose receptor–expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. 2015;56(8):1265–71.
Boss SD, et al. Reduced 18F-folate conjugates as a new class of PET tracers for folate receptor imaging. Bioconj Chem. 2018;29(4):1119–30.
Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.
Brand C, et al. Development of a new folate-derived Ga-68-based PET imaging agent. Mol Imaging Biol. 2017;19(5):754–61.
Cannarile MA, et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):1–13.
Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.
Cendrowicz E, et al. The role of macrophages in cancer development and therapy. Cancers. 2021;13(8):1946.
Chandrupatla DMSH, et al. Imaging and methotrexate response monitoring of systemic inflammation in arthritic rats employing the macrophage PET tracer [18F] fluoro-PEG-folate. Contrast Med Mol Imaging. 2018;2018:8092781.
Chen Q, et al. Folate-PEG-NOTA-Al18F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors. Mol Pharm. 2017;14(12):4353–61.
Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition. Onco Targets Ther. 2018;11:3817.
Chen Y, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):1–13.
Chistiakov DA, et al. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology. 2018;223(1):101–11.
Choi PS, et al. Synthesis and evaluation of 68 Ga-HBED-CC-EDBE-folate for positron-emission tomography imaging of overexpressed folate receptors on CT26 tumor cells. J Label Compd Radiopharm. 2018;61(1):4–10.
Clemente GS, et al. Mapping arginase expression with 18F-fluorinated late-generation arginase inhibitors derived from quaternary α-amino acids. J Nucl Med. 2021;62(8):1163–70.
Deci MB, et al. Modulating macrophage polarization through CCR2 inhibition and multivalent engagement. Mol Pharm. 2018;15(7):2721–31.
Eichendorff S, et al. Biodistribution and PET imaging of a novel [68 Ga]-anti-CD163-antibody conjugate in rats with collagen-induced arthritis and in controls. Mol Imaging Biol. 2015;17(1):87–93.
English SJ, et al. CCR2 positron emission tomography for the assessment of abdominal aortic aneurysm inflammation and rupture prediction. Circ Cardiovasc Imaging. 2020;13(3):e009889.
Fischer JA, Rossetti S, Sacchi N. CSF1R (colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (V-FMS) oncogene homolog). http://AtlasGeneticsOncology.org (2009): 120.
Galli F, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39:1–21.
Gonçalo SC, et al. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. Int J Mol Sci. 2020;21(15):5291.
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.
Graversen JH, Moestrup SK. Drug trafficking into macrophages via the endocytotic receptor CD163. Membranes. 2015;5(2):228–52.
Grzywa TM, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.
Hao Q, Vadgama JV, Wang P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020;18:1–13.
Horti AG, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci. 2019;116(5):1686–91.
Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.
Jamiyan T, et al. CD68-and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Arch. 2020;477(6):767–75.
Jeong H, et al. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22(1):38–51.
Jung J, Zeng Hu, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21(1):85–93.
Kambara K, et al. In vivo depletion of CD206+ M2 macrophages exaggerates lung injury in endotoxemic mice. Am J Pathol. 2015;185(1):162–71.
Kim EJ, et al. Novel PET imaging of atherosclerosis with 68Ga-labeled NOTA-neomannosylated human serum albumin. J Nucl Med. 2016;57(11):1792–7.
Kurahara H, et al. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol. 2012;19(7):2264–71.
Li C, et al. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J ImmunoTherapy Cancer. 2021;9(1):e001341.
Lubowicka E, et al. Plasma chemokine CCL2 and its receptor CCR2 concentrations as diagnostic biomarkers for breast cancer patients. BioMed Res Int. 2018;2018:2124390.
Malyshev I, Malyshev Y. Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage “switch” phenotype. Biomed Res Int. 2015;2015:341308.
Mir MA. Developing costimulatory molecules for immunotherapy of diseases. Cambridge: Academic Press; 2015.
Mukherjee S, et al. The yin and yang of imaging tumor associated macrophages with PET and MRI. Theranostics. 2019;9(25):7730.
Murphy K, Weaver C. Janeway’s immunobiology. New York: Garland Science; 2016.
Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116(12):1499–504.
Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–21.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.
Pilleron S, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49–58.
Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. 2018;8:49.
Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018;16(1):1–8.
PrabhuDas MR, et al. A consensus definitive classification of scavenger receptors and their roles in health and disease. J Immunol. 2017;198(10):3775–89.
Puig-Kröger A, et al. Folate receptor β is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 2009;69(24):9395–403.
Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.
Qi L, et al. IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma. Oncotarget. 2016;7(44):71673.
Quail DF, Joyce JA. Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res. 2017;23(4):876–84.
Rath M, et al. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:532.
Russell DG, Huang Lu, VanderVen BC. Immunometabolism at the interface between macrophages and pathogens. Nat Rev Immunol. 2019;19(5):291–304.
Schniering J, et al. 18F-AzaFol for detection of folate receptor-β positive macrophages in experimental interstitial lung disease—a proof-of-concept study. Front Immunol. 2019;10:2724.
Shen J, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2018;9(4):4485.
Silva RA, et al. CTHRSSVVC peptide as a possible early molecular imaging target for atherosclerosis. Int J Mol Sci. 2016;17(9):1383.
Silvola JMU, et al. Aluminum fluoride-18 labeled folate enables in vivo detection of atherosclerotic plaque inflammation by positron emission tomography. Sci Rep. 2018;8(1):1–15.
Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ macrophages in inflammatory and malignant diseases. Int J Mol Sci. 2020;21(15):5497.
Sosnik A. From the “magic bullet” to advanced nanomaterials for active targeting in diagnostics and therapeutics. In: Biomedical applications of functionalized nanomaterials. Elsevier, 2018. 1–32.
Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Tahara N, et al. 2-deoxy-2-[18 F] fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20(2):215–9.
Tanzey SS, et al. Synthesis and initial in vivo evaluation of [11C] AZ683—a novel PET radiotracer for colony stimulating factor 1 receptor (CSF1R). Pharmaceuticals. 2018;11(4):136.
Tap WD, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–37.
Thomas AC, Mattila JT. “Of mice and men”: arginine metabolism in macrophages. Front Immunol. 2014;5:479.
Tsai W-T, Wu AM. Aligning physics and physiology: E ngineering antibodies for radionuclide delivery. J Labelled Compd Radiopharm. 2018;61(9):693–714.
Tsaur I, et al. CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat. 2015;47(2):306.
Valero JG, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;10:1–15.
Varasteh Z, et al. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68 Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Res. 2019;9(1):1–10.
Veremeyko T, et al. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor CEBPβ. Front Immunol. 2018;9:2515.
Verweij NJF, et al. First in man study of [18 F] fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Sci Rep. 2020;10(1):1–10.
Vinogradov S, Warren G, Wei X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine. 2014;9(5):695–707.
Wagner S, et al. Development of the first potential nonpeptidic positron emission tomography tracer for the imaging of CCR2 receptors. ChemMedChem. 2021;16(4):640.
Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36(10):1085–93.
Xavier C, et al. Clinical translation of [68 Ga] Ga-NOTA-anti-MMR-sdAb for PET/CT imaging of protumorigenic macrophages. Mol Imaging Biol. 2019;21(5):898–906.
Yang C, et al. Elevated CD163+/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer. Int J Biol Sci. 2019;15(5):984.
Zhang S-Y, et al. Tumor-associated macrophages: a promising target for a cancer immunotherapeutic strategy. Pharmacol Res. 2020;161:105111.
Zhang X, et al. CC chemokine receptor 2-targeting copper nanoparticles for positron emission tomography-guided delivery of gemcitabine for pancreatic ductal adenocarcinoma. ACS Nano. 2021;15(1):1186–98.
Zhou J, et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188.
Zhou X, et al. PET imaging of colony-stimulating factor 1 receptor: a head-to-head comparison of a novel radioligand, 11C-GW2580, and 11C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey. J Cereb Blood Flow Metab. 2021;41(9):2410–22.